Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:26 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 3,500 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

NCT01100502
View directory record Official record
Conditions
Disease, Hodgkin
Interventions
brentuximab vedotin, placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
32
States / cities
Duarte, California • San Francisco, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional

Comparing Two Ways of Controlling Blood Sugar With Insulin in Patients Admitted to the Intensive Care Unit

NCT00166491
View directory record Official record
Conditions
Critical Illness, Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Evaluation Perioperative Nutrition on Donor Site Healing in Patients Undergoing Reconstructive Burn Surg

NCT00539097
View directory record Official record
Conditions
Burn, Reconstructive Surgical Procedure
Interventions
Juven (Ross Products) protein supplement
Dietary Supplement
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
6 Years to 24 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 3 Interventional

Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer

NCT00003070
View directory record Official record
Conditions
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
enalapril maleate, quality-of-life assessment
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
8 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
55
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Nov 3, 2026, 11:26 AM EST
Active, not recruiting Phase 3 Interventional

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Tiragolumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management

NCT02944656
View directory record Official record
Conditions
Pain
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 2 Interventional Results available

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

NCT02362451
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
Autologus elutriated monocyte placebo vaccine, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 2 Interventional Results available

A Study of Sublingual Immunotherapy in Peanut-allergic Children

NCT00597727
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Peanut SLIT, Placebo SLIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 4 Interventional Results available

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

NCT00381095
View directory record Official record
Conditions
Bone Neoplasms, Pain, Intractable, Cancer
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Celebration, Florida • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 2 Interventional Results available

Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD

NCT00752557
View directory record Official record
Conditions
Osteoporosis
Interventions
rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy), bisphosphonates, calcium, and vitamin D
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3457263 in Obese Participants

NCT05582096
View directory record Official record
Conditions
Overweight, Obesity
Interventions
LY3457263, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 2Phase 3 Interventional Results available

Vancomycin for Primary Sclerosing Cholangitis

NCT03710122
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
Elizabeth Carey
Other
Eligibility
18 Years to 76 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Determine if Fibrin Affects the Ability of a Wound to Heal

NCT01253135
View directory record Official record
Conditions
Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray
Interventions
Fibrin, White Petrolatum
Biological · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Nov 3, 2026, 11:26 AM EST
Not listed Phase 2 Interventional

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

NCT00110708
View directory record Official record
Conditions
Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions
Oralgam (human immunoglobulin)
Drug
Lead sponsor
PediaMed Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 2 Interventional Results available

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions
NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional Results available

Decision Support for Intraoperative Low Blood Pressure

NCT02726620
View directory record Official record
Conditions
Hypotension
Interventions
Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 100 Years
Enrollment
22,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 2 Interventional Results available

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

NCT03457818
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Osteoporosis
Interventions
Denosumab 60 mg/ml [Prolia], Placebo
Drug · Other
Lead sponsor
Mishaela Rubin
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Nov 3, 2026, 11:26 AM EST
Not listed Phase 4 Interventional

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

NCT04414579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Faster Insulin Aspart (Fiasp®)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 4 Interventional Results available

Preemptive Analgesia Following Uterine Artery Embolization

NCT01555073
View directory record Official record
Conditions
Uterine Fibroids, Uterine Artery Embolization
Interventions
pregabalin/celecoxib, pregabalin/placebo, celecoxib/placebo, Placebo group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 4 Interventional Results available

Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

NCT04376762
View directory record Official record
Conditions
Pediatric HD, Bleeding
Interventions
Fibrinogen, Cryoprecipitate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
Up to 24 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
View directory record Official record
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent
Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Nov 3, 2026, 11:26 AM EST
Recruiting Phase 2Phase 3 Interventional

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

NCT05664789
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N acetyl cysteine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 3, 2026, 11:26 AM EST
Not yet recruiting Not applicable Interventional

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

NCT06748950
View directory record Official record
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Nov 3, 2026, 11:26 AM EST